BioStem Technologies’ Press Release and Conference Call Offered Encouraging News

BioStem Technologies Inc
From Jason Matuszewski, CEO of BioStem Technologies (BSEM), who stated, “BioStem had an outstanding fourth quarter. Revenue reached $11.5 million, nearly 14 times higher than revenue of roughly $0.8 million for last year’s comparable quarter. The growth was driven by the successful commercial launch into the private office setting of AmnioWrap2, our innovative placental-derived allograft product designed to . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.